Literature DB >> 19579024

Multicenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma.

Hiroshi Kurita1, Etsuhide Yamamoto, Shinichi Nozaki, Shigehito Wada, Isao Furuta, Masaru Miyata, Kenji Kurashina.   

Abstract

PURPOSE: To determine the clinical and hisotological efficacy and toxicities of induction chemotherapy with docetaxel (DOC) and nedaplatin (CDGP) for oral squamous cell carcinoma (OSCC) in the preoperative setting.
METHODS: A total of 30 patients with locally advanced but operable OSCC were enrolled. Combination induction chemotherapy consisted of DOC 60 mg/m2 followed by CDGP 100 mg/m2.
RESULTS: All patients received one cycle of chemotherapy. In the clinical assessment, ten patients achieved partial response for an overall response rate of 33.3% (95% CI, 16.4-50.2%). Histological assessment of surgical specimens showed an overall response rate of 56.6% (95% CI, 38.9-74.3%). Although severe neutropenia was observed in 90% of patients, only one patient (3.3%) experienced severe infection. Toxicities associated with this regimen did not interfere with planned radical surgery.
CONCLUSIONS: A single cycle of preoperative combination chemotherapy with DOC and CDGP showed moderate histological activity with an acceptable safety profile for the planned radical surgery. Further studies testing more cycles before surgery might be more appropriate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19579024     DOI: 10.1007/s00280-009-1056-z

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  5 in total

1.  Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.

Authors:  Bret D Wallace; Hongwei Wang; Kimberly T Lane; John E Scott; Jillian Orans; Ja Seol Koo; Madhukumar Venkatesh; Christian Jobin; Li-An Yeh; Sridhar Mani; Matthew R Redinbo
Journal:  Science       Date:  2010-11-05       Impact factor: 47.728

2.  Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions.

Authors:  Yuki Kawarada; Masayuki Miyazaki; Ayaka Itoh; Risa Araki; Hidetaka Iwamizu; Tomomi Kataoka; Yasuo Kumakura; Akiko Ota; Taku Nagai; Kiyofumi Yamada
Journal:  Int J Clin Oncol       Date:  2017-01-25       Impact factor: 3.402

3.  Nedaplatin: a cisplatin derivative in cancer chemotherapy.

Authors:  Muneaki Shimada; Hiroaki Itamochi; Junzo Kigawa
Journal:  Cancer Manag Res       Date:  2013-05-08       Impact factor: 3.989

4.  Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.

Authors:  Yoshihiro Tanaka; Kazuhiro Yoshida; Toshiyuki Tanahashi; Naoki Okumura; Nobuhisa Matsuhashi; Kazuya Yamaguchi
Journal:  Cancer Sci       Date:  2016-05-12       Impact factor: 6.716

5.  Nedaplatin as a Single-Agent Chemotherapy May Support Palliative Therapy for Patients with Adenoid Cystic Carcinoma: A Case Report.

Authors:  Hiroyuki Hirakawa; Takayoshi Kiba; Yuko Saito; Yoshiteru Watanabe; Takahiro Suzuki; Nobuo Ota
Journal:  Case Rep Oncol       Date:  2017-08-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.